Feasibility Assessment of a Medical Device for Tumour Cell Retention and Radiotherapy Sensitization in Patients With Suspected High-grade Glioma

This is a prospective, multicenter, single-arm, pilot clinical investigation, aimed at evaluating the safety and preliminary efficacy of the GlioHook implant in patients with high-grade glioma undergoing surgical resection followed by standard of care (SoC) treatment. GlioHook is a sterile medical device designed to be implanted after tumour resection surgery in suspected high grade glioma patients, covering the entire surface of the tumour resection margins, decreasing infiltration and focalizing the disease, while improving the effects of radiotherapy. Once implanted, GlioHook exerts a dual mechanism that combines tumour cell focalization and radiosensitization.

NCT Number	NCT07725640
Lead Sponsor	Batea Oncology Collaborators: Apices Soluciones S.L.
Conditions	Glioma, High-Grade Glioma (HGG), Surgical Resection
Enrollment	15 participants
Start Date	2026-10-30
Primary Completion	2028-10-30 (estimated)
Study Completion	2028-10-30 (estimated)
Updated on ClinicalTrials.gov	2026-07-27